Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Yupi Indo Jelly Gum corrects IPO proceeds-use report, cites IDR 541.37 billion remaining funds

Yupi Indo Jelly Gum corrects IPO proceeds-use report, cites IDR 541.37 billion remaining funds

BitgetBitget2026/10/13 10:03
  • PT Yupi Indo Jelly Gum Tbk issued a correction to its July 15, 2026 report on the use of IPO proceeds.
  • Gross IPO proceeds totaled IDR 612.64 billion; offering costs were IDR 15.97 billion; net proceeds were IDR 596.67 billion.
  • Realized use of funds reached IDR 55.3 billion, leaving IDR 541.37 billion unspent.
  • Unspent proceeds were placed mainly in bank deposits and current accounts, including Panin, CTBC, OCBC Syariah, BTPN Syariah.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PT Yupi Indo Jelly Gum Tbk published the original content used to generate this news brief via Indonesia Stock Exchange (IDX) (Ref. ID: 32165974) on October 13, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss